Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Research Report 2024
After vaccination, the body can produce a humoral immune response. It is used to prevent infectious diseases caused by group A and group C meningococci, such as cerebrospinal meningitis and pneumonia.
According to Mr Accuracy reports’s new survey, global Group A and Group C Meningococcal Polysaccharide Vaccine market is projected to reach US$ 425.5 million in 2034, increasing from US$ 285 million in 2024, with the CAGR of 5.9% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Group A and Group C Meningococcal Polysaccharide Vaccine market research.
Meningococcal disease, caused by Neisseria meningitidis, can cause serious illness and even death. The global burden of meningococcal disease, especially serogroups A and C, drives the need for effective vaccines to prevent these infections.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Group A and Group C Meningococcal Polysaccharide Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Walvax
Lanzhou Institute of Biological Products
AIM Bio
Sanofi Pasteur
GSK
Hualan Bio
ZFSW
Changsheng
Kanghua Bio
Segment by Type
Class 1 Vaccine
Class II Vaccine
Hospital
Clinic
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Group A and Group C Meningococcal Polysaccharide Vaccine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Group A and Group C Meningococcal Polysaccharide Vaccine market is projected to reach US$ 425.5 million in 2034, increasing from US$ 285 million in 2024, with the CAGR of 5.9% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Group A and Group C Meningococcal Polysaccharide Vaccine market research.
Meningococcal disease, caused by Neisseria meningitidis, can cause serious illness and even death. The global burden of meningococcal disease, especially serogroups A and C, drives the need for effective vaccines to prevent these infections.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Group A and Group C Meningococcal Polysaccharide Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Walvax
Lanzhou Institute of Biological Products
AIM Bio
Sanofi Pasteur
GSK
Hualan Bio
ZFSW
Changsheng
Kanghua Bio
Segment by Type
Class 1 Vaccine
Class II Vaccine
Segment by Application
Hospital
Clinic
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Group A and Group C Meningococcal Polysaccharide Vaccine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices